A phase 1 dual‐dose escalation study of radiation and nab‐paclitaxel in patients with unresectable and borderline resectable pancreatic cancer
Cancer · 2025
DOI: 10.1002/cncr.35936 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Cancer, 2025. Verfasst von Uri Amit und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Tel Aviv Medical Center, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Paclitaxel, Albumins, Chemoradiotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: University of Pennsylvania.
Abstract (Originalsprache)
Background
This phase 1 dual dose‐escalation study aimed to evaluate the safety, feasibility, and toxicity profile of combining dose‐escalated radiation therapy with high‐dose nab‐paclitaxel in patients with unresectable or borderline resectable pancreatic cancer. Methods and Materials Twenty‐one evaluable patients were enrolled and allocated three radiation dose levels, 55 Gy, 57.5 Gy, and 60 Gy, administered over 5 weeks in 25 fractions. Concurrent nab‐paclitaxel was given weekly at a dose of 125 mg/m 2 . Radiation dose escalation was guided by a time‐to‐event continual reassessment method. Toxicities were classified according to CTCAE v4.0, with dose‐limiting toxicities (DLT) defined as grade 3 or higher gastrointestinal events or substantial decline in performance status. Surgical resection was pursued in patients achieving sufficient tumor downstaging.
Results
Hematologic toxicities were the most common grade ≥3 adverse events occurring in 76.2% of patients. Nonhematologic toxicities were less frequent (57.1%). Two grade 3 gastrointestinal DLT cases occurred at dose levels 57.5 Gy and 60 Gy. The maximum tolerated dose was 60 Gy with a probability of DLT of 0.155 at this dose. Surgical resection with negative margins was achieved in 33.3% of patients, including all borderline resectable cases and 22.2% of initially unresectable cases. The median overall survival and time to local progression from the start of radiation therapy were 22.3 months and 20.3 months, respectively.
Conclusions
This study demonstrates the feasibility and safety of combining dose‐escalated radiation with high‐dose nab‐paclitaxel in locally advanced pancreatic cancer. The regimen is associated with manageable toxicity and promising local control and survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Tel Aviv Medical Center, Tel Aviv, Israel.
- Department of Radiation Oncology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
- Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
- Department of Surgery, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
- Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Uri Amit
Förderung
- University of Pennsylvania
Zitieren
APA
Amit, U., Metz, J. M., Plastaras, J. P., Gheewala, R., Teitelbaum, U., Damjanov, N., Vollmer, C., Schneider, C. J., Lee, M. K., O'Hara, M., Reiss-Binder, K., Carpenter, E. L., Karasic, T. B., Konski, A., Wileyto, E. P., & Ben-Josef, E. (2025). A phase 1 dual‐dose escalation study of radiation and nab‐paclitaxel in patients with unresectable and borderline resectable pancreatic cancer. Cancer. https://doi.org/10.1002/cncr.35936
Vancouver
Amit U, Metz JM, Plastaras JP, Gheewala R, Teitelbaum U, Damjanov N, et al. A phase 1 dual‐dose escalation study of radiation and nab‐paclitaxel in patients with unresectable and borderline resectable pancreatic cancer. Cancer. 2025. doi:10.1002/cncr.35936
BibTeX
@article{Amit2025,
author = {Amit, Uri and Metz, James M and Plastaras, John P and Gheewala, Rohi and Teitelbaum, Ursina and Damjanov, Nevena and Vollmer, Charles and Schneider, Charles J and Lee, Major Kenneth and O'Hara, Mark and Reiss-Binder, Kim and Carpenter, Erica L and Karasic, Thomas B and Konski, Andre and Wileyto, E Paul and Ben-Josef, Edgar},
title = {A phase 1 dual‐dose escalation study of radiation and nab‐paclitaxel in patients with unresectable and borderline resectable pancreatic cancer},
journal = {Cancer},
year = {2025},
doi = {10.1002/cncr.35936}
}
EUVIMED